dostęp otwarty
Nebiwolol i bisoprolol w terapii nadciśnienia tętniczego i chorób towarzyszących – konsensus ekspertów
Afiliacje- Katedra i Klinika Chorób Wewnętrznych, Nadciśnienia Tętniczego i Onkologii Klinicznej, Wydział Lekarski, Uniwersytet Medyczny we Wrocławiu
dostęp otwarty
Streszczenie
Beta-adrenolityki niezmiennie od wielu lat pozostają jedną z podstawowych grup leków wydłużających życie u pacjentów z chorobami układu sercowo-naczyniowego. Istnieje jednak wiele różnic wewnątrzklasowych — od farmakokinetyki i farmakodynamiki do charakterystycznych efektów działania swoistych dla poszczególnych przedstawicieli, które stają się istotne w personalizacji terapii osób z chorobami układu krążenia przy schorzeniach współistniejących. W niniejszym opracowaniu dokonano syntetycznego pozycjonowania leków beta-adrenolitycznych w terapii chorób układu sercowo-naczyniowego i schorzeń współistniejących. Ze względu na obszerność zagadnienia przedstawiono syntetyczne porównanie dwóch najczęściej stosowanych i najbardziej kardioselektywnych beta-adrenolityków — bisoprololu i nebiwololu — w aspekcie ich skuteczności i bezpieczeństwa stosowania w określonym kontekście klinicznym.
Streszczenie
Beta-adrenolityki niezmiennie od wielu lat pozostają jedną z podstawowych grup leków wydłużających życie u pacjentów z chorobami układu sercowo-naczyniowego. Istnieje jednak wiele różnic wewnątrzklasowych — od farmakokinetyki i farmakodynamiki do charakterystycznych efektów działania swoistych dla poszczególnych przedstawicieli, które stają się istotne w personalizacji terapii osób z chorobami układu krążenia przy schorzeniach współistniejących. W niniejszym opracowaniu dokonano syntetycznego pozycjonowania leków beta-adrenolitycznych w terapii chorób układu sercowo-naczyniowego i schorzeń współistniejących. Ze względu na obszerność zagadnienia przedstawiono syntetyczne porównanie dwóch najczęściej stosowanych i najbardziej kardioselektywnych beta-adrenolityków — bisoprololu i nebiwololu — w aspekcie ich skuteczności i bezpieczeństwa stosowania w określonym kontekście klinicznym.
Słowa kluczowe
nebiwolol; bisoprolol; beta-adrenolityki; terapia spersonalizowana; wytyczne; nadciśnienie tętnicze; choroby współistniejące
Informacje o artykuleTytuł
Nebiwolol i bisoprolol w terapii nadciśnienia tętniczego i chorób towarzyszących – konsensus ekspertów
Czasopismo
Nadciśnienie Tętnicze w Praktyce
Numer
Typ artykułu
Artykuł przeglądowy
Strony
1-16
Opublikowany online
2022-04-15
Wyświetlenia strony
1669
Wyświetlenia/pobrania artykułu
3126
Rekord bibliograficzny
Nadciśnienie Tętnicze w Praktyce 2022;8(1):1-16.
Słowa kluczowe
nebiwolol
bisoprolol
beta-adrenolityki
terapia spersonalizowana
wytyczne
nadciśnienie tętnicze
choroby współistniejące
Autorzy
Adrian Doroszko
Piotr Dobrowolski
Aleksander Prejbisz
Krzysztof J. Filipiak
Andrzej Januszewicz
Krzysztof Narkiewicz
Agnieszka Olszanecka
Andrzej Tykarski
Jacek Wolf
Referencje (67)- Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
- Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1–86.
- Williams B, MacDonald TM, Morant S, et al. British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015; 386(10008): 2059–2068.
- Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
- Collet JP, Thiele H, Barbato E, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
- Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
- Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
- Brugada J, Katritsis DG, Arbelo E, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020; 41(5): 655–720.
- Czuriga I, Riecansky I, Bodnar J, et al. NEBIS Investigators, NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003; 17(3): 257–263.
- Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009; 54(16): 1491–1499.
- Zhao Y, Vanhoutte PM, Leung SWS. Vascular nitric oxide: Beyond eNOS. J Pharmacol Sci. 2015; 129(2): 83–94.
- Montezano AC, Dulak-Lis M, Tsiropoulou S, et al. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol. 2015; 31(5): 631–641.
- Seleme VB, Marques GL, Mendes AE, et al. Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2021; 21(2): 165–180.
- Sawa M, Harada H. Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists. Curr Med Chem. 2006; 13(1): 25–37.
- Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol. 2009; 53(5): 379–387.
- Olawi N, Krüger M, Grimm D, et al. Nebivolol in the treatment of arterial hypertension. Basic Clin Pharmacol Toxicol. 2019; 125(3): 189–201.
- Wehland M, Grosse J, Simonsen U, et al. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease. Curr Vasc Pharmacol. 2012; 10(3): 378–390.
- Del Pinto R, Ferri C, Parati G. Reduction of blood pressure variability: an additional protective cardiovascular effect of vasodilating beta-blockers? J Hypertens. 2020; 38(3): 405–407.
- Ferri C. The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines. Future Cardiol. 2021; 17(8): 1421–1433.
- Grassi G. Sympathetic overdrive in hypertension: clinical and theraputic relevance. J Cardiol Pract. 2015; 13. ; 24.
- Zeng W, Tomlinson B. Temporal haemodynamic changes after bisoprolol treatment in patients with uncontrolled hypertension. Ann Transl Med. 2021; 9(11): 923.
- Leopold G, Pabst J, Ungethüm W, et al. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol. 1986; 26(8): 616–621.
- Fares A. Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients. J Cardiovasc Dis Res. 2011; 2(3): 153–155.
- Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol. 1997; 51(6): 493–498.
- Leopold G, Pabst J, Ungethüm W, et al. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol. 1986; 26(8): 616–621.
- Briciu C, Neag M, Muntean D, et al. Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. Clujul Med. 2015; 88(2): 208–213.
- AlHabeeb W, Mrabeti S, Abdelsalam AA. Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovasc Drugs Ther. 2021 [Epub ahead of print].
- Stoschitzky K, Stoschitzky G, Klein W, et al. Different Effects of Exercise on Plasma Concentrations of Nebivolol, Bisoprolol and Carvedilol. Cardiovasc Drugs and Ther. 2004; 18(2): 135–138.
- Stoschitzky K. Additional Features of Beta-Blockers. Heart Drug. 2005; 5(1): 6–10.
- Lip GYH. Atrial Fibrillation in Patients With Hypertension: Trajectories of Risk Factors in Yet Another Manifestation of Hypertensive Target Organ Damage. Hypertension. 2016; 68(3): 544–545.
- McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Ferri C, Pasqualetti P, Tiberti S, et al. Electrophysiological effects of short-term antihypertensive therapy. Expert Rev Cardiovasc Ther. 2008; 6(10): 1343–1346.
- Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937–952.
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957–967.
- Ambrosio G, Flather MD, Böhm M, et al. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart. 2011; 97(3): 209–214.
- Canepa M, Franssen FME, Olschewski H, et al. Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. JACC Heart Fail. 2019; 7(10): 823–833.
- Pité H, da Cruz MB, Morais-Almeida M. Obstructive lung diseases and beta-blockers: Where do we stand? Eur J Intern Med. 2016; 34: e32–e33.
- Paolillo S, Dell'Aversana S, Esposito I, et al. The use of β-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues. Eur J Intern Med. 2021; 88: 9–14.
- National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007. J Allergy Clin Immunol. 2007; 120(5): S94–S138.
- Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002; 137(9): 715–725.
- Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014; 145(4): 779–786.
- Negro RWD, Tognella S, Micheletto C. Pharmacokinetics of the Effect of Nebivolol 5mg on Airway Patency in Patients with Mild to Moderate Bronchial Asthma and Arterial Hypertension. Clin Drug Invest. 2002; 22(3): 197–204.
- Martiniuc C, Branishte T. The use of beta blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Rev Med Chir Soc Med Nat Iasi. 2012; 116(1): 218–221.
- Sinagra G, Corrà U, Contini M, et al. Choosing among β-blockers in heart failure patients according to β-receptors' location and functions in the cardiopulmonary system. Pharmacol Res. 2020; 156: 104785.
- Contini M, Apostolo A, Cattadori G, et al. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial. Int J Cardiol. 2013; 168(3): 2134–2140.
- Verdecchia P, Cavallini C, Coiro S, et al. Certainties fading away: β-blockers do not worsen chronic obstructive pulmonary disease. Eur Heart J Suppl. 2021; 23(Suppl E): E172–E176.
- Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Mustafaev II, Nurmamedova GS. [Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension]. Kardiologiia. 2013; 53(2): 48–54.
- Vertkin AL, Loran OB, Topolianskiĭ AV, et al. [Clinical effectiveness of beta-adrenoblockers and their effects on copulative function in patients with hypertension]. Kardiologiia. 2002; 42(9): 39–42.
- Gür Ö, Gurkan S, Yumun G, et al. The Comparison of the Effects of Nebivolol and Metoprolol on Erectile Dysfunction in the Cases with Coronary Artery Bypass Surgery. Ann Thorac Cardiovasc Surg. 2017; 23(2): 91–95.
- Cordero A, Bertomeu-Martínez V, Mazón P, et al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther. 2010; 28(1): 15–22.
- Rosen RC, Kostis JB, Jekelis A, et al. Sexual sequelae of antihypertensive drugs: treatment effects on self-report and physiological measures in middle-aged male hypertensives. Arch Sex Behav. 1994; 23(2): 135–152.
- Paolillo S, Dell'Aversana S, Esposito I, et al. The use of β-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues. Eur J Intern Med. 2021; 88: 9–14.
- Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003; 24(21): 1928–1932.
- Simova II, Todorova-Konstantinova RR, Denchev SV. Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients. Exp Clin Cardiol. 2009; 14(4): 45–49.
- Viigimaa M, Vlachopoulos C, Doumas M, et al. European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. J Hypertens. 2020; 38(7): 1220–1234.
- Broekman CP, Haensel SM, Van de Ven LL, et al. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther. 1992; 18(4): 325–331.
- Wai B, Kearney LG, Hare DL, et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012; 11: 14.
- Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004; 292(18): 2227–2236.
- Del Mauro JS, Prince PD, Allo MA, et al. Effects of third-generation β-blockers, atenolol or amlodipine on blood pressure variability and target organ damage in spontaneously hypertensive rats. J Hypertens. 2020; 38(3): 536–545.
- Mirault T, Galloula A, Cambou JP, et al. Impact of betablockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease: The COPART Registry. Medicine (Baltimore). 2017; 96(5): e5916.
- Aboyans V, Ricco JB, Bartelink MLEL, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763–816.
- Espinola-Klein C, Weisser G, Jagodzinski A, et al. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011; 58(2): 148–154.
- Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol. 2017; 33(11): 1342–1433.
- Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136(6): e137–e161.
- van der Meer P, Gaggin HK, Dec GW. ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. J Am Coll Cardiol. 2019; 73(21): 2756–2768.
